DISCLOSURES
Dr. Shapiro is an investigator for RegenLab. Dr. Lo Sicco is an
investigator for RegenLab. The other authors have no conflicts
of interest to disclose.
REFERENCES
1. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020.
2. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411-2418.
3. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525.
4. Ladapo JA, McKinnon JE, McCullough PA, et al. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death:meta-analysis. medRxiv 2020.09.30.20204693; doi:https://doi.org/10.1101/2020.09.30.20204693.
5. Grau-Pujol B, Camprub  D, Marti-Soler H, et al. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial. Trials. 2020;21(1):688.
6. NYC Health Department COVID-19 Data Files. Github, v1; 2020. https:// github.com/nychealth/coronavirus-data
7. Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020;83(1):308-309.
8. Salvarani C, Mancuso P, Gradellini F, et al. Susceptibility to COVID-19 in patients treated with antimalarials: a population based study in Emilia- Romagna, Northern Italy. Arthritis Rheumatol. 2020.
2. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411-2418.
3. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525.
4. Ladapo JA, McKinnon JE, McCullough PA, et al. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death:meta-analysis. medRxiv 2020.09.30.20204693; doi:https://doi.org/10.1101/2020.09.30.20204693.
5. Grau-Pujol B, Camprub  D, Marti-Soler H, et al. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial. Trials. 2020;21(1):688.
6. NYC Health Department COVID-19 Data Files. Github, v1; 2020. https:// github.com/nychealth/coronavirus-data
7. Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020;83(1):308-309.
8. Salvarani C, Mancuso P, Gradellini F, et al. Susceptibility to COVID-19 in patients treated with antimalarials: a population based study in Emilia- Romagna, Northern Italy. Arthritis Rheumatol. 2020.
AUTHOR CORRESPONDENCE
Kristen I. Lo Sicco MD Kristen.LoSicco@nyulangone.org
